剑指全球市场！诺和诺德(NVO.US)扩建爱尔兰工厂 欲借口服版Wegovy抢占市场份额

Core Viewpoint - Novo Nordisk (NVO.US) plans to increase investment in Ireland to produce an oral version of its popular weight loss drug Wegovy for markets outside the U.S. [1] Group 1: Investment Plans - The company will expand its production facility in Athlone, central Ireland, although the CEO did not disclose the scale of the investment [1]. - The investment in Ireland signifies the company's commitment to regaining its position in the weight loss market despite increasing price competition [1]. Group 2: Product Performance - Wegovy's oral version was launched in early January and has become one of the most successful drug launches in history, with over 240,000 patients in the U.S. currently using it [1]. - The oral drug is seen as a crucial tool for Novo Nordisk to close the gap with competitors like Eli Lilly (LLY.US) [1]. Group 3: Market Context - Ireland is recognized as a global hub for pharmaceutical manufacturing, with Eli Lilly also producing active ingredients for its weight loss and diabetes drugs there [1]. - The Irish economy is heavily reliant on U.S. investments and is currently under the spotlight due to tariff threats from former President Trump [1].